• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于约束 α,γ-AA 肽骨架开发安全广谱的醛酮酰胺 Mpro 抑制剂。

Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold.

机构信息

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL 33620, USA.

Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, 85721, USA.

出版信息

Chemistry. 2023 Jun 22;29(35):e202300476. doi: 10.1002/chem.202300476. Epub 2023 May 5.

DOI:10.1002/chem.202300476
PMID:36920943
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10330001/
Abstract

SARS-CoV-2 is still wreaking havoc all over the world with surging morbidity and high mortality. The main protease (M ) is essential in the replication of SARS-CoV-2, enabling itself an active target for antiviral development. Herein, we reported the design and synthesis of a new class of peptidomimetics-constrained α, γ-AA peptides, based on which a series of aldehyde and ketoamide inhibitors of the M of SARS-CoV-2 were prepared. The lead compounds showed excellent inhibitory activity in the FRET-based M enzymatic assay not only for the M of SARS-CoV-2 but also for SARS-CoV and MERS-CoV, along with HCoVs like HCoV-OC43, HCoV-229E, HCoV-NL63 and HKU1. The X-ray crystallographic results demonstrated that our compounds form a covalent bond with the catalytic Cys145. They also demonstrated effective antiviral activity against live SARS-CoV-2. Overall, the results suggest that α, γ-AA peptide could be a promising molecular scaffold in designing novel M inhibitors of SARS-CoV-2 and other coronaviruses.

摘要

SARS-CoV-2 仍在全球范围内肆虐,发病率和死亡率居高不下。主蛋白酶(M )在 SARS-CoV-2 的复制中至关重要,使其成为抗病毒药物开发的一个活跃靶点。在此,我们报告了一类基于肽拟肽的新型Constrained α, γ-AA 肽的设计和合成,在此基础上,我们制备了一系列 SARS-CoV-2 M 的醛和酮酰胺抑制剂。基于荧光共振能量转移(FRET )的 M 酶测定法,这些先导化合物不仅对 SARS-CoV-2 的 M ,而且对 SARS-CoV 和 MERS-CoV ,以及 HCoV 如 HCoV-OC43、HCoV-229E、HCoV-NL63 和 HKU1 ,均表现出优异的抑制活性。X 射线晶体学结果表明,我们的化合物与催化 Cys145 形成共价键。它们还对活 SARS-CoV-2 表现出有效的抗病毒活性。总体而言,这些结果表明,α, γ-AA 肽可能是设计新型 SARS-CoV-2 和其他冠状病毒主蛋白酶抑制剂的有前途的分子支架。

相似文献

1
Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold.基于约束 α,γ-AA 肽骨架开发安全广谱的醛酮酰胺 Mpro 抑制剂。
Chemistry. 2023 Jun 22;29(35):e202300476. doi: 10.1002/chem.202300476. Epub 2023 May 5.
2
Synthesis and multitarget inhibitory effect of indole-based ethyl cinnamate derivatives against SARS-CoV-2 M and cathepsins for broad-spectrum anti-coronavirus activity.基于吲哚的肉桂酸乙酯衍生物对SARS-CoV-2 M蛋白和组织蛋白酶的合成及其多靶点抑制作用以实现广谱抗冠状病毒活性
Bioorg Med Chem. 2025 Oct 1;128:118258. doi: 10.1016/j.bmc.2025.118258. Epub 2025 May 23.
3
'Vivaldi': an amplicon-based whole-genome sequencing method for the four seasonal human coronaviruses, 229E, NL63, OC43 and HKU1, alongside SARS-CoV-2.“维瓦尔第”:一种基于扩增子的全基因组测序方法,用于检测四种季节性人类冠状病毒(229E、NL63、OC43和HKU1)以及严重急性呼吸综合征冠状病毒2(SARS-CoV-2)
Microb Genom. 2025 Jul;11(7). doi: 10.1099/mgen.0.001451.
4
Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4).通过受体转运蛋白 4(RTP4)限制 SARS-CoV-2 的复制。
mBio. 2023 Aug 31;14(4):e0109023. doi: 10.1128/mbio.01090-23. Epub 2023 Jun 29.
5
Amphibian-Derived Peptides as Natural Inhibitors of SARS-CoV-2 Main Protease (M): A Combined In Vitro and In Silico Approach.源自两栖动物的肽作为严重急性呼吸综合征冠状病毒2主蛋白酶(M)的天然抑制剂:体外和计算机模拟相结合的方法
Chem Biodivers. 2025 Jun;22(6):e202403202. doi: 10.1002/cbdv.202403202. Epub 2025 Feb 6.
6
A Comparison of Conserved Features in the Human Coronavirus Family Shows That Studies of Viruses Less Pathogenic than SARS-CoV-2, Such as HCoV-OC43, Are Good Model Systems for Elucidating Basic Mechanisms of Infection and Replication in Standard Laboratories.人类冠状病毒家族保守特征的比较表明,对致病性低于SARS-CoV-2的病毒(如HCoV-OC43)的研究是在标准实验室中阐明感染和复制基本机制的良好模型系统。
Viruses. 2025 Feb 13;17(2):256. doi: 10.3390/v17020256.
7
Development of a sensitive high-throughput enzymatic assay capable of measuring sub-nanomolar inhibitors of SARS-CoV2 Mpro.开发一种灵敏的高通量酶法测定法,能够测定 SARS-CoV2 Mpro 的亚纳摩尔抑制剂。
SLAS Discov. 2024 Sep;29(6):100179. doi: 10.1016/j.slasd.2024.100179. Epub 2024 Aug 14.
8
Development of Primer Panels for Whole-Genome Amplification and Sequencing of Human Seasonal Coronaviruses: hCoV-OC43, hCoV-HKU1, hCoV-229E, and hCoV-NL63.用于人类季节性冠状病毒全基因组扩增和测序的引物组的开发:人冠状病毒OC43、人冠状病毒HKU1、人冠状病毒229E和人冠状病毒NL63
Viruses. 2024 Dec 25;17(1):13. doi: 10.3390/v17010013.
9
Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.在动物模型中,通过治疗给药,有效的 3CLpro 抑制剂对 SARS-CoV-2 和 MERS-CoV 有效。
mBio. 2024 Feb 14;15(2):e0287823. doi: 10.1128/mbio.02878-23. Epub 2023 Dec 21.
10
Discovery of Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors through Rational Design of Novel Fluorinated 1,3,4-oxadiazole Amide Derivatives: An In-Silico Study.通过新型氟化1,3,4-恶二唑酰胺衍生物的合理设计发现严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂:一项计算机模拟研究
Chem Biodivers. 2025 Jun;22(6):e202403179. doi: 10.1002/cbdv.202403179. Epub 2025 Feb 14.

引用本文的文献

1
Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.探索新型冠状病毒主要蛋白酶的共价抑制剂:从拟肽到新型骨架
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2460045. doi: 10.1080/14756366.2025.2460045. Epub 2025 Feb 6.
2
On the origins of SARS-CoV-2 main protease inhibitors.关于严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的起源
RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25.

本文引用的文献

1
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.SARS-CoV-2 对奈玛特韦产生耐药性的多种途径。
Nature. 2023 Jan;613(7944):558-564. doi: 10.1038/s41586-022-05514-2. Epub 2022 Nov 9.
2
A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.一种新型的基于环状γ-氨基酸肽的长效泛冠状病毒融合抑制剂,通过靶向刺突蛋白中的两个位点具有潜在的口服生物利用度。
Cell Discov. 2022 Sep 8;8(1):88. doi: 10.1038/s41421-022-00455-6.
3
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations.
奈玛特韦(PF-07321332)的历史、作用机制及前景:一种口服生物利用度良好的主要蛋白酶抑制剂,与利托那韦联合使用以减少与COVID-19相关的住院治疗。
Med Chem Res. 2022;31(10):1637-1646. doi: 10.1007/s00044-022-02951-6. Epub 2022 Aug 30.
4
Sulfono-γ-AApeptides as Protein Helical Domain Mimetics to Manipulate the Angiogenesis.磺酰基-γ-AA 肽作为蛋白质螺旋结构域模拟物来调控血管生成。
Chembiochem. 2022 Nov 18;23(22):e202200298. doi: 10.1002/cbic.202200298. Epub 2022 Sep 12.
5
The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition.奥密克戎 SARS-CoV-2 主要蛋白酶中的 P132H 突变降低了热稳定性,但不影响催化作用或小分子药物抑制效果。
Cell Res. 2022 May;32(5):498-500. doi: 10.1038/s41422-022-00640-y. Epub 2022 Mar 15.
6
Non-covalent SARS-CoV-2 M inhibitors developed from in silico screen hits.基于计算机筛选命中物开发的非共价 SARS-CoV-2 M 抑制剂。
Sci Rep. 2022 Feb 15;12(1):2505. doi: 10.1038/s41598-022-06306-4.
7
Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor.通过血管内皮生长因子的蛋白质模拟物调节血管生成。
J Am Chem Soc. 2022 Jan 12;144(1):270-281. doi: 10.1021/jacs.1c09571. Epub 2021 Dec 30.
8
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.二卤代和三卤代乙酰胺类化合物作为共价 SARS-CoV-2 主蛋白酶抑制剂的发现:具有高靶标特异性。
J Am Chem Soc. 2021 Dec 15;143(49):20697-20709. doi: 10.1021/jacs.1c08060. Epub 2021 Dec 3.
9
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays.使用Flip-GFP和蛋白酶-Glo荧光素酶检测法对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶抑制剂进行验证和失效验证。
Acta Pharm Sin B. 2022 Apr;12(4):1636-1651. doi: 10.1016/j.apsb.2021.10.026. Epub 2021 Nov 1.
10
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.